1. Technical Field
The disclosed subject matter relates generally to the field of nerve stimulation. More specifically, the invention relates to a method and system of optimizing parameter settings for nerve stimulation.
2. Background Information
Various diseases and disorders of the nervous system are associated with abnormal neural discharge patterns. One treatment regimen for such diseases and disorders includes drug therapy. Another treatment technique includes the implantation of an implantable medical device having a pulse generator for electrically stimulating (i.e., applying an electrical signal to) a target location of the patient's neural tissue, such as a cranial nerve. In one such available treatment for epilepsy, the vagus nerve (the tenth cranial nerve) is electrically stimulated by a neurostimulator device substantially as described in one or more of U.S. Pat. Nos. 4,702,254, 4,867,164, and 5,025,807, all of which are incorporated herein by reference.
Some implantable pulse generators used for electrical stimulation of neurological tissue operate according to a therapy algorithm programmed into the device by a physician or other health care provider. One or more therapy parameters or the actual software running on the neurostimulator may be changed after implantation by reprogramming the neurostimulator via transcutaneous communication between an external programming device and the implanted neurostimulator. The ability to program (and later re-program) the implanted medical device (“IMD”) permits a health care provider to customize the therapy provided by the IMD to the patient's needs, to update the therapy periodically should those needs change, and to update the software of the device, including the operating system, as improved and/or revised therapy regimens are developed.
However, in many cases, the physician will not know a suitable or optimal range of parameter settings within which to operate the neurostimulator. Each patient may have different levels of tolerance and reaction to nerve stimulation. Thus, some patients may have to be stimulated differently (e.g., different current levels, different frequencies, etc.) than other patients to respond to the therapy. Complicating selection of nerve stimulation therapies and parameters is the fact that many implantable medical devices are battery-operated. Different therapies may result in a different level of drain on the device's battery. All else being equal, one would prefer for the battery to last as long as possible.
Methods and systems for determining an optimal therapeutic window of parameter settings for nerve stimulation therapy are described herein. The disclosed techniques generally utilize one or more parameter sweeps to determine upper and lower threshold settings for an individual patient. The determination of the optimal therapeutic window may be performed during surgery to implant an implantable medical device. In one embodiment, this could be accomplished using a temporary electrode coupled to the nerve during the surgical procedure. The temporary electrode may be removed at the conclusion of the optimization process. Alternatively, a permanent electrode for sensing electrical activity on the nerve may be attached to the nerve and coupled to the implantable medical device for non-invasively optimizing therapeutic windows after surgery.
In at least one embodiment, a method comprises delivering an electrical signal to a nerve according to at least a first and second parameter. The method also comprises measuring an electrical response of the nerve to the electrical signal. In addition, the method comprises adjusting the first parameter while the second parameter remains constant. The method further comprises repeating the aforementioned acts to acquire a plurality of electrical responses and determining a lower threshold setting and an upper threshold setting from the plurality of electrical responses.
In another embodiment, a method comprises delivering a plurality of electrical signals to a nerve according to a plurality of current amplitudes and a constant pulse width. The method additionally comprises recording a plurality of electrical responses of the nerve to the plurality of electrical signals. Furthermore, the method comprises determining at least one lower threshold setting and at least one upper threshold setting from the plurality of electrical responses of the nerve.
In a further embodiment, a system comprises a processor and software executable on the processor. The software causes the processor to instruct an implantable medical device to deliver a plurality of electrical signals to a nerve according to at least first and second parameters. The first parameter is iteratively adjusted while the second parameter remains fixed. The software also instructs the processor to detect a plurality of electrical responses of the nerve to the plurality of electrical signals applied to the nerve, and to determine a lower threshold setting and an upper threshold setting from the plurality of electrical responses based on a fixed second parameter.
The described methods and systems provide a user with settings at which an implantable medical device can operate with improved (e.g., optimal) energy efficiency. As a result, a physician is provided with a known, and generally optimal, range of parameter settings for therapy for an individual patient without the need for extensive trial and error.
The foregoing has outlined rather broadly certain features and advantages of the disclosed embodiments in order that the detailed description that follows may be better understood. Additional features may be described hereinafter that form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims.
For a detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying drawings in which:
Certain terms are used throughout the following description and claims to refer to particular system components. This document does not intend to distinguish between components that differ in name but not function.
In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . ”. Also, the term “couple” or “couples” is intended to mean either an indirect or direct electrical connection. Thus, if a first device couples to a second device, that connection may be through a direct electrical connection, or through an indirect electrical connection via other devices and connections.
“Compound action potential” means a group of almost synchronous nerve fiber action potentials from the trunk of a motor, sensory, or mixed nerve. Compound action potentials may be evoked by nerve stimulation and are recorded as a multi-peaked summed action potential.
“Parameter sweep” means a test conducted employing at least two parameters that can be varied, the test progressively increasing or decreasing a first parameter within a specified range while keeping a second parameter constant.
The present invention is susceptible to implementation in various embodiments. The disclosure of specific embodiments, including preferred embodiments, is not intended to limit the scope of the invention as claimed unless expressly specified in the claims. In addition, persons skilled in the art will understand that the invention has broad application. Accordingly, the discussion of particular embodiments is meant only to be exemplary, and does not imply that the scope of the disclosure, including the claims, is limited to specifically disclosed embodiments.
The following description is presented largely in terms of vagus nerve stimulation (“VNS”), in which the electrical signal is applied to the vagus nerve. However, the disclosure and claims that follow are not limited to VNS, and may be applied to the delivery of an electrical signal to modulate the electrical activity of other cranial nerves such as the trigeminal and/or glossopharyngeal nerves, or to other neural tissue such as one or more brain structures of the patient, spinal nerves, and other spinal structures. Further still, other embodiments of the invention can be implemented to stimulate tissue other than nerves or neural tissue, such as cardiac tissue.
It is recognized that a minimum level of stimulation by a battery-powered VNS device is required to evoke action potentials on a nerve. The minimum stimulation level may be a function of a number of different parameters and is generally unique to each patient. Further, as the level of stimulation is increased from the minimum level, the ability to invoke action potentials may also increase. There is, however, a point of “diminishing returns” in that, at some point, further increases to the level of stimulation does not produce a statistically significant increase in action potential response, and thus only serves to unnecessarily drain the battery that powers the VNS device.
The following embodiments assist in the determination, for a given patient, of a minimum level as well as a maximum level that generally corresponds to a point of diminishing returns. Measurements are made on the patient to facilitate these computations. In at least some embodiments, the measurements are made during surgery to implant the VNS device. The process comprises implanting the VNS device and employing a temporary cuff electrode assembly that is coupled to the target nerve. The cuff electrode assembly connects to an external system that initiates the process of stimulating the nerve and measuring the response. After the measurements are made, the cuff electrode assembly is removed from the patient and the implantation surgery can be completed.
Referring still to
In the embodiment of
Referring still to
Programming device 124 preferably includes a central processing unit (CPU) 236 such as a low-power, mixed-signal microcontroller. In general, any suitable processor can be used to implement the functionality performed by the programming device 124 as explained herein. It will be appreciated that some features of the programming system 120 may also be provided in whole, or in part, by the IMD 110, and vice versa. Thus, while certain features of the present invention may be described as being included as part of the IMD 110, it is not intended thereby to preclude embodiments in which the features are provided by the programming system 120. Likewise, describing certain features herein as part of the programming system 120 is not intended to preclude embodiments in which the features are included as part of the IMD 110.
The CPU 236 is preferably coupled to storage 250. The CPU 236 may interpret, manipulate, and/or analyze the data received from removable cuff assembly electrodes 136. The storage 250 may comprise volatile (e.g., random access memory) and/or non-volatile storage (e.g., read only memory (ROM), electrically-erasable programmable ROM (EEPROM), Flash memory, etc.). Storage 250 may comprise any suitable storage medium. Examples of suitable storage media include without limitation, USB flash drives, Compact Flash cards, memory sticks, Smart Media cards, Secure Digital (SD) cards, xD cards, CD-ROM, DVD-ROM, tape drives, Zip disks, floppy disk, RAM, hard drives, etc. The storage 250 may be used to store code (e.g., diagnostic software 380, discussed below) that is executed by the CPU 236. The executable code may be executed directly from the non-volatile memory or copied to the volatile memory for execution therefrom.
The storage 250 may also be used to store the parameter settings, any one or more of which can be programmed into the IMD 110 by the programming system 120. The parameters include, for example, pulse width, current amplitude, frequency, on time, off time, etc. The parameters define the nature of the electrical signal to be delivered to the nerve 113.
In accordance with certain embodiments, the programming device 124 includes the diagnostic program 380. During implantation, the programming system 120 can be used and the diagnostic software 380 executed to cause the IMD 110 to repeatedly stimulate the patient's nerve 113 in accordance with various programming system-provided parameters. Through cuff assembly 130, the programming system is informed of the electrical activity on the nerve that results from the various IMD-generated electrical signals. The resulting evoked electrical activity and sensed data are analyzed by, for example, the programming system 120 to determine lower and upper threshold settings. In at least one embodiment, the diagnostic software 280 causes a first stimulation parameter (e.g., current amplitude) to be iteratively adjusted while keeping a second parameter (e.g., pulse width) constant. This process is referred to as a parameter sweep. A lower threshold setting represents the parameter settings that correspond to a lower threshold. The term “lower threshold” is the minimum electrical stimulation level necessary to evoke a compound action potential response.
An upper threshold setting represents the parameter settings corresponding to an upper threshold. The upper threshold is an electrical stimulation level above which no statistically significant increase in action potential is obtainable by further increasing the level of stimulation (i.e., the point of diminishing returns).
As explained above, the diagnostic software 380 operates to adjust iteratively a first parameter (e.g., current amplitude) while holding a second parameter constant (e.g., pulse width). Once that parameter sweep is completed, the diagnostic software 380 may adjust the second parameter (e.g., pulse width) to one or more different settings and again perform a first parameter sweep for each subsequent second parameter setting. The diagnostic software 380 is described in more detail below.
The programming device also includes a display 232. Preferably, the programming device 124 is capable of displaying a waveform of a compound action potential from a nerve on the display 232. In preferred embodiments, a user may input parameter settings using an input device 238 through a graphical user interface on the display 232, or other input means. Storage 250 stores the measured compound action potential amplitudes received from sensing electrode 130 as well as the corresponding parameter settings which caused the compound action potential.
In certain embodiments, the programming system 120 comprises an amplifier 244 and an A/D converter 246. The amplifier 244 and A/D converter 246 may be part of the programming device 124 or separate from the programming device 124. The amplifier 244 amplifies analog signals received from sensing electrodes 136 while the A/D converter 246 converts the amplified analog signal from the electrodes 136 to a digital signal representation for the programming device 124 to process. In this embodiment, the parameter settings, lower threshold settings, upper threshold settings, and measured amplitudes are stored on storage 250.
In block 302, the diagnostic software 380 is initiated. Typically, a user initiates the diagnostic software 380 by way of the programming device 124. The programming device 124 then instructs the IMD 110 to proceed and execute the diagnostic software 380. The diagnostic software 380 preferably is stored in storage 250 of programming device 124 and is executed by the CPU 236. Alternatively, the diagnostic software 380 is downloaded from the programming device 124 to the IMD 110 immediately before starting method 300. In another embodiment, the diagnostic software 380 is pre-loaded in the IMD 110. In yet other embodiments, method 300 is performed manually without the need for diagnostic software 380.
In general, the diagnostic software 380 contains one or more parameters at pre-programmed settings at which to stimulate the nerve to determine lower and upper threshold settings. The diagnostic software 380 may also define a preset range for each parameter. By way of example only, the diagnostic software may contain instructions to stimulate the nerve at three pulse widths in 100 μs increments (250 μsec, 350 μsec, and 450 μsec,) and at each pulse width, testing seven current levels ranging from 0.25 mA to 1.75 mA at 0.25 mA intervals (See Table 1).
However, the diagnostic software 380 may comprise any number of settings for a particular parameter. In an actual implementation, a “sweep” could consist of any desired step change in current and pulse width, e.g., smaller or larger increments than the 0.25 mA and 100 μsec examples discussed above. By providing smaller step sizes, a better resolution of the threshold window may be provided. In alternative embodiments, before implantation, a user may enter the desired range, parameters, parameter settings, and/or parameter increments to be tested into the programming device 124.
The diagnostic software 380 also comprises an initial parameter setting which is incapable of evoking a compound action potential response in a nerve. In block 303, the programming device 124 instructs the IMD 110 to begin at the initial parameter setting by programming the IMD 110 with the initial parameter values. Once the IMD 110 has been set to the initial parameter values, the IMD 110 delivers the electrical signal to the nerve in block 304 according to the initial parameter setting in block 303. Typically, the programming device 124 instructs the IMD 110 to deliver the electrical signal, which preferably comprises one more pulses in accordance with the specified parameter settings (e.g., 10 pulses/sec at a specified current amplitude for 5 seconds).
In block 306, programming device 124 measures and stores the amplitudes of the response in data storage 250. In embodiments where a plurality of electrical pulses are delivered at a parameter setting, programming device 124 calculates, for example, an average amplitude from the plurality of responses caused by the plurality of electrical pulses. The programming device 124 then records the calculated average amplitude in storage 250. Further, in block 307, the present parameter setting programmed into the IMD 110 is recorded in data storage 250 and associated with stored response data.
In further embodiments, block 306 comprises detecting a trigger signal 180 from the IMD 110 (
In block 308, the diagnostic software 380 checks to see if further first parameter settings (e.g., current amplitudes) are to be tested. If additional first parameter settings to be tested during the present parameter sweep, the method proceeds to block 309. At block 309, programming device 124 instructs the IMD 110 to adjust iteratively the first parameter (e.g., current) while keeping the second parameter (e.g., pulse width) constant. In other words, electrical signals are delivered at a plurality of different current amplitudes, but at a constant pulse width. Examples of parameters that may be varied include without limitation current amplitude, pulse-width, frequency, duty cycle, etc. Any combination and number of parameters may be tested. After adjusting the first parameter, the programming device 124 then instructs the IMD 110 to deliver the electrical signal at the new parameter setting at block 304.
If all first parameter settings have been tested for a given second parameter setting, the method 300 proceeds to block 311. If the diagnostic software 380 contains instructions for additional second parameters to be tested, the method proceeds to block 310. At block 310, the second parameter is adjusted. For example, the pulse width may be changed from 250 μsec to 350 μsec. The programming device 124 also instructs the IMD 110 to reset the first parameter to its initial setting. The process then proceeds to block 304 and the first parameter sweep is repeated, this time with a different second parameter.
Once the diagnostic software 380 has completed parameter sweeps for all of the second parameter settings, the method 300 proceeds to block 312. In block 312, the programming system 120 determines the lower and upper threshold settings for each second parameter setting. Thus, for example, if a current amplitude sweep is performed for each of three pulse widths, the programming system 120 determines three sets of lower/upper threshold settings—one for each pulse width. The lower threshold setting comprises the lowest first parameter setting (e.g., current amplitude) at which a compound action potential is detected via the electrodes 136 for a given second parameter setting. In an alternative embodiment (not shown), upper and/or lower thresholds may be determined at any desired point within a sweep of the first parameter or the second parameter. Such a method could be used to abort unnecessary parameter sweep settings and thereby avoid unnecessary electrical signals being delivered to the patient. For example, once an upper threshold has been determined during a first parameter sweep, the system may abort any programmed first parameter settings exceeding that for the determined upper threshold.
The upper threshold setting comprises a maximum first parameter setting above which, all else being equal, no statistically significant increase in action potential magnitude is observed for a given second parameter setting. In one embodiment, a current amplitude parameter sweep is performed for a given pulse width. The current amplitudes programmed into the IMD 110 start low and are increased by the programming system 120. For each IMD current amplitude, the programming system senses the resulting electrical response (voltage potential) induced on the nerve. At some point, the increase in nerve response voltage potential resulting from one current amplitude to the next (i.e. higher) current amplitude, while possibly increasing, ceases to increase very much. A determination can thus be made that, if the nerve response voltage potential does not increase more than a specified amount, the upper threshold setting has been reached. The specified amount can be expressed in terms of voltage potential or a percentage of a predetermined value of voltage potential. The specified amount can be hard-coded into the diagnostic software 380 or programmable.
Once the upper threshold and lower threshold settings have been determined, the parameter settings are stored in storage 250 and identified as the upper and lower threshold settings. In a preferred embodiment, the result of method 300 is, at least in part, the lower and upper threshold settings corresponding to each second parameter setting (pulse width). The result of method 300 may also include a set of parameter settings between the lower and upper threshold settings as well as the corresponding recorded compound action potential amplitudes. The upper and lower threshold settings may be downloadable or recorded on removable storage medium. A physician or user may utilize the information to plot customized operating curves for each patient on the display 232. An example of such a plot is shown in
In a variation of method 300, amplitudes and parameters may not be recorded until a lower threshold is reached. If a compound action potential response has not occurred in response to electrical stimulation, the method 300 may proceed to a separate lower threshold determining step (not shown). If a lower threshold has not been reached, blocks 304, 306 and 308 are repeated until the programming device 120 determines that a compound action potential response occurs. Once a lower threshold is reached, the data i.e. parameter setting, compound action potential amplitude, is recorded in data storage 250 and identified as a lower threshold setting. After a lower threshold has been reached, data may be continuously recorded in storage 250 until an upper threshold is reached.
In an embodiment, the programming device performs a separate upper threshold determining step after block 307 (not shown). If the programming device 124 has determined that an upper threshold has not been reached, then the method 300 may proceed to 308. However, if the programming device has determined that an upper threshold has been reached, the corresponding parameter settings may be identified and the method 300 may proceed to block 311.
The system and method described herein cause measurements to be made for a given patient to determine, for each of a plurality of pulse widths (or other parameter), the minimum amount of current (or other parameter) needed to evoke an electrical response on a nerve and an upper amount of current above which it is determined that no further therapeutic benefit is achieved and battery would simply be wasted. Healthcare providers can use this data to treat the patient. The data includes a suitable or optimal range of values to be programmed for that particular patient.
Although certain embodiments of the present invention have been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
3760812 | Timm et al. | Sep 1973 | A |
3796221 | Hagfors | Mar 1974 | A |
4107469 | Jenkins | Aug 1978 | A |
4305402 | Katims | Dec 1981 | A |
4338945 | Kosugi et al. | Jul 1982 | A |
4424812 | Lesnick | Jan 1984 | A |
4431000 | Butler et al. | Feb 1984 | A |
4459989 | Borkan | Jul 1984 | A |
4503863 | Katims | Mar 1985 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4577316 | Schiff | Mar 1986 | A |
4590946 | Loeb | May 1986 | A |
4592339 | Kuzmak et al. | Jun 1986 | A |
4606349 | Livingston et al. | Aug 1986 | A |
4608985 | Crish et al. | Sep 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4625308 | Kim et al. | Nov 1986 | A |
4628942 | Sweeney et al. | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4702254 | Zarbara | Oct 1987 | A |
4793353 | Borkan | Dec 1988 | A |
4867164 | Zabara | Sep 1989 | A |
4920979 | Bullara | May 1990 | A |
4949721 | Toriu et al. | Aug 1990 | A |
4977895 | Tannenbaum | Dec 1990 | A |
5025807 | Zarbara | Jun 1991 | A |
5081987 | Nigam | Jan 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5354320 | Schaldach et al. | Oct 1994 | A |
5411531 | Hill et al. | May 1995 | A |
5411540 | Edell et al. | May 1995 | A |
5423872 | Cigaina | Jun 1995 | A |
5507784 | Hill et al. | Apr 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5522865 | Schulman et al. | Jun 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5601617 | Loeb et al. | Feb 1997 | A |
5611350 | John | Mar 1997 | A |
5645570 | Corbucci | Jul 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690688 | Noren et al. | Nov 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5702428 | Tippey et al. | Dec 1997 | A |
5702429 | King | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5792212 | Weijand | Aug 1998 | A |
5800474 | Benabid et al. | Sep 1998 | A |
5814092 | King | Sep 1998 | A |
5836994 | Bourgeois | Nov 1998 | A |
5861014 | Familoni | Jan 1999 | A |
5913882 | King | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
5995868 | Dorfmeister et al. | Nov 1999 | A |
6002966 | Loeb et al. | Dec 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6041258 | Cigaina et al. | Mar 2000 | A |
6083249 | Familoni | Jul 2000 | A |
6101412 | Duhaylongsod | Aug 2000 | A |
6104955 | Bourgeois | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6132361 | Epstein et al. | Oct 2000 | A |
6141590 | Renirie et al. | Oct 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6175764 | Loeb et al. | Jan 2001 | B1 |
6188929 | Giordano | Feb 2001 | B1 |
6219580 | Faltys et al. | Apr 2001 | B1 |
6221908 | Kilgard et al. | Apr 2001 | B1 |
6238423 | Bardy | May 2001 | B1 |
6249704 | Maltan et al. | Jun 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6266564 | Hill et al. | Jul 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6295472 | Rubinstein et al. | Sep 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6308102 | Sieracki | Oct 2001 | B1 |
6324421 | Stadler et al. | Nov 2001 | B1 |
6327503 | Familoni | Dec 2001 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6353762 | Baudino et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6358203 | Bardy | Mar 2002 | B2 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6366814 | Boveja | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6381493 | Stadler et al. | Apr 2002 | B1 |
6381496 | Meadows et al. | Apr 2002 | B1 |
6381499 | Taylor et al. | Apr 2002 | B1 |
6418344 | Rezai et al. | Jul 2002 | B1 |
6425852 | Epstein et al. | Jul 2002 | B1 |
6438423 | Rezai et al. | Aug 2002 | B1 |
6449512 | Boveja | Sep 2002 | B1 |
6453199 | Kobozev | Sep 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6463328 | John | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477417 | Levine | Nov 2002 | B1 |
6477418 | Plicchi et al. | Nov 2002 | B2 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6484132 | Hively et al. | Nov 2002 | B1 |
6487446 | Hill et al. | Nov 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6522928 | Whitehurst et al. | Feb 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6549804 | Osorio et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6564102 | Boveja | May 2003 | B1 |
6565503 | Leysieffer et al. | May 2003 | B2 |
6579280 | Kovach et al. | Jun 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587724 | Mann | Jul 2003 | B2 |
6587726 | Lurie et al. | Jul 2003 | B2 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6594524 | Esteller et al. | Jul 2003 | B2 |
6600953 | Flesler et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6609031 | Law et al. | Aug 2003 | B1 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6612983 | Marchal | Sep 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6615084 | Cigaina | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6656960 | Puskas | Dec 2003 | B2 |
6662053 | Borkan | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671547 | Lyster et al. | Dec 2003 | B2 |
6671555 | Gielen et al. | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684104 | Gordon et al. | Jan 2004 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6690973 | Hill et al. | Feb 2004 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6708064 | Rezai | Mar 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6731979 | MacDonald | May 2004 | B2 |
6731986 | Mann | May 2004 | B2 |
6754536 | Swoyer et al. | Jun 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6764498 | Mische | Jul 2004 | B2 |
6768969 | Nikitin et al. | Jul 2004 | B1 |
6775573 | Schuler et al. | Aug 2004 | B2 |
6793670 | Osorio et al. | Sep 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6853862 | Marchal et al. | Feb 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6895278 | Gordon | May 2005 | B1 |
6904390 | Nikitin et al. | Jun 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6934580 | Osorio et al. | Aug 2005 | B1 |
6944501 | Pless | Sep 2005 | B1 |
6961618 | Osorio et al. | Nov 2005 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7006872 | Gielen et al. | Feb 2006 | B2 |
7050856 | Stypulkowski | May 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7146217 | Firlik et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7177678 | Osorio et al. | Feb 2007 | B1 |
7188053 | Nikitin et al. | Mar 2007 | B2 |
7204833 | Osorio et al. | Apr 2007 | B1 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7231254 | DiLorenzo | Jun 2007 | B2 |
7236830 | Gliner | Jun 2007 | B2 |
7236831 | Firlik et al. | Jun 2007 | B2 |
7242983 | Frei et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7340302 | Falkenberg et al. | Mar 2008 | B1 |
20010034541 | Lyden | Oct 2001 | A1 |
20010037220 | Merry et al. | Nov 2001 | A1 |
20020052539 | Haller et al. | May 2002 | A1 |
20020065509 | Lebel et al. | May 2002 | A1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020082480 | Riff et al. | Jun 2002 | A1 |
20020099412 | Fischell et al. | Jul 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020120310 | Linden et al. | Aug 2002 | A1 |
20020133204 | Hrdlicka | Sep 2002 | A1 |
20020143368 | Bakels et al. | Oct 2002 | A1 |
20020151939 | Rezai | Oct 2002 | A1 |
20020153901 | Davis et al. | Oct 2002 | A1 |
20020188214 | Misczynski et al. | Dec 2002 | A1 |
20030028226 | Thompson et al. | Feb 2003 | A1 |
20030055457 | MacDonald | Mar 2003 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030083716 | Nicolelis et al. | May 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030095648 | Kaib et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030109903 | Berrang et al. | Jun 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield et al. | Jul 2003 | A1 |
20030135248 | Stypulkowski | Jul 2003 | A1 |
20030144711 | Pless et al. | Jul 2003 | A1 |
20030144829 | Geatz et al. | Jul 2003 | A1 |
20030181954 | Rezai | Sep 2003 | A1 |
20030181958 | Dobak | Sep 2003 | A1 |
20030181959 | Dobak | Sep 2003 | A1 |
20030208212 | Cigaina | Nov 2003 | A1 |
20030210147 | Humbard | Nov 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040006278 | Webb et al. | Jan 2004 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040036377 | Mezinis | Feb 2004 | A1 |
20040039424 | Merritt et al. | Feb 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040111139 | McCreery | Jun 2004 | A1 |
20040112894 | Varma | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040122485 | Stahmann et al. | Jun 2004 | A1 |
20040122489 | Mazar et al. | Jun 2004 | A1 |
20040133119 | Osorio et al. | Jul 2004 | A1 |
20040138516 | Osorio et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138518 | Rise et al. | Jul 2004 | A1 |
20040138647 | Osorio et al. | Jul 2004 | A1 |
20040138711 | Osorio et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040147992 | Bluger et al. | Jul 2004 | A1 |
20040153129 | Pless et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040158165 | Yonce et al. | Aug 2004 | A1 |
20040167583 | Knudson et al. | Aug 2004 | A1 |
20040167587 | Thompson | Aug 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040172089 | Whitehurst et al. | Sep 2004 | A1 |
20040172091 | Rezai | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040176831 | Gliner et al. | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199146 | Rogers et al. | Oct 2004 | A1 |
20040199187 | Loughran | Oct 2004 | A1 |
20040199212 | Fischell et al. | Oct 2004 | A1 |
20040210270 | Erickson | Oct 2004 | A1 |
20040210274 | Bauhahn et al. | Oct 2004 | A1 |
20040249302 | Donoghue et al. | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20040260346 | Overall et al. | Dec 2004 | A1 |
20040263172 | Gray et al. | Dec 2004 | A1 |
20050004615 | Sanders | Jan 2005 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050010262 | Rezai et al. | Jan 2005 | A1 |
20050015128 | Rezai et al. | Jan 2005 | A1 |
20050016657 | Bluger | Jan 2005 | A1 |
20050020887 | Goldberg | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021106 | Firlik et al. | Jan 2005 | A1 |
20050021107 | Firlik et al. | Jan 2005 | A1 |
20050021118 | Genau et al. | Jan 2005 | A1 |
20050027284 | Lozano et al. | Feb 2005 | A1 |
20050028026 | Shirley et al. | Feb 2005 | A1 |
20050033378 | Sheffield et al. | Feb 2005 | A1 |
20050033379 | Lozano et al. | Feb 2005 | A1 |
20050038326 | Mathur | Feb 2005 | A1 |
20050038484 | Knudson et al. | Feb 2005 | A1 |
20050049515 | Misczynski et al. | Mar 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050060007 | Goetz | Mar 2005 | A1 |
20050060008 | Goetz | Mar 2005 | A1 |
20050060009 | Goetz | Mar 2005 | A1 |
20050060010 | Goetz | Mar 2005 | A1 |
20050065562 | Rezai | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065574 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070971 | Fowler et al. | Mar 2005 | A1 |
20050075679 | Gliner et al. | Apr 2005 | A1 |
20050075680 | Lowry et al. | Apr 2005 | A1 |
20050075681 | Rezai et al. | Apr 2005 | A1 |
20050075691 | Phillips et al. | Apr 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050088145 | Loch | Apr 2005 | A1 |
20050101873 | Misczynski et al. | May 2005 | A1 |
20050102002 | Salo et al. | May 2005 | A1 |
20050107753 | Rezai et al. | May 2005 | A1 |
20050107842 | Rezai | May 2005 | A1 |
20050107858 | Bulger | May 2005 | A1 |
20050113705 | Fischell et al. | May 2005 | A1 |
20050113744 | Donoghue et al. | May 2005 | A1 |
20050119703 | DiLorenzo | Jun 2005 | A1 |
20050124901 | Misczynski et al. | Jun 2005 | A1 |
20050131467 | Boveja et al. | Jun 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050131506 | Rezai et al. | Jun 2005 | A1 |
20050137480 | Alt et al. | Jun 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050143786 | Boveja et al. | Jun 2005 | A1 |
20050148893 | Misczynski et al. | Jul 2005 | A1 |
20050148894 | Misczynski et al. | Jul 2005 | A1 |
20050148895 | Misczynski et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154435 | Stern et al. | Jul 2005 | A1 |
20050159789 | Brockway et al. | Jul 2005 | A1 |
20050161052 | Rezai et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050177192 | Rezai et al. | Aug 2005 | A1 |
20050177200 | George et al. | Aug 2005 | A1 |
20050177206 | North et al. | Aug 2005 | A1 |
20050182389 | LaPorte et al. | Aug 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050187593 | Housworth et al. | Aug 2005 | A1 |
20050187796 | Rosenfeld et al. | Aug 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197590 | Osorio et al. | Sep 2005 | A1 |
20050222631 | Dalal et al. | Oct 2005 | A1 |
20050228693 | Webb et al. | Oct 2005 | A1 |
20050240246 | Lee et al. | Oct 2005 | A1 |
20050245944 | Rezai | Nov 2005 | A1 |
20050245971 | Brockway et al. | Nov 2005 | A1 |
20050245990 | Roberson | Nov 2005 | A1 |
20050261542 | Riehl | Nov 2005 | A1 |
20050267550 | Hess et al. | Dec 2005 | A1 |
20050272280 | Osypka | Dec 2005 | A1 |
20050277872 | Colby et al. | Dec 2005 | A1 |
20050277998 | Tracey et al. | Dec 2005 | A1 |
20050283200 | Rezai et al. | Dec 2005 | A1 |
20050283201 | Machado et al. | Dec 2005 | A1 |
20050283208 | Von Arx et al. | Dec 2005 | A1 |
20050288600 | Zhang et al. | Dec 2005 | A1 |
20050288736 | Persen et al. | Dec 2005 | A1 |
20050288760 | Machado et al. | Dec 2005 | A1 |
20060009815 | Boveja | Jan 2006 | A1 |
20060020292 | Goetz et al. | Jan 2006 | A1 |
20060020491 | Mongeon et al. | Jan 2006 | A1 |
20060041222 | Dewing et al. | Feb 2006 | A1 |
20060041223 | Dewing et al. | Feb 2006 | A1 |
20060041287 | Dewing et al. | Feb 2006 | A1 |
20060047205 | Ludomirsky et al. | Mar 2006 | A1 |
20060052843 | Elsner et al. | Mar 2006 | A1 |
20060058597 | Machado et al. | Mar 2006 | A1 |
20060064133 | Von Arx et al. | Mar 2006 | A1 |
20060064134 | Mazar et al. | Mar 2006 | A1 |
20060064143 | Von Arx et al. | Mar 2006 | A1 |
20060069322 | Zhang et al. | Mar 2006 | A1 |
20060074450 | Boveja | Apr 2006 | A1 |
20060079936 | Boveja | Apr 2006 | A1 |
20060079942 | Deno et al. | Apr 2006 | A1 |
20060079945 | Libbus | Apr 2006 | A1 |
20060085046 | Rezai et al. | Apr 2006 | A1 |
20060094971 | Drew | May 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060100667 | Machado et al. | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060106431 | Wyler et al. | May 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060122525 | Shusterman | Jun 2006 | A1 |
20060122667 | Chavan et al. | Jun 2006 | A1 |
20060122864 | Gottesman et al. | Jun 2006 | A1 |
20060135877 | Giftakis et al. | Jun 2006 | A1 |
20060135881 | Giftakis et al. | Jun 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060161459 | Rosenfeld et al. | Jul 2006 | A9 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173522 | Osorio | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195155 | Firlik et al. | Aug 2006 | A1 |
20060195163 | KenKnight et al. | Aug 2006 | A1 |
20060200206 | Firlik et al. | Sep 2006 | A1 |
20060212091 | Lozano et al. | Sep 2006 | A1 |
20060217780 | Gliner et al. | Sep 2006 | A1 |
20060220839 | Fifolt et al. | Oct 2006 | A1 |
20060224067 | Giftakis et al. | Oct 2006 | A1 |
20060224191 | DiLorenzo | Oct 2006 | A1 |
20060241697 | Libbus et al. | Oct 2006 | A1 |
20060241725 | Libbus et al. | Oct 2006 | A1 |
20060253164 | Zhang et al. | Nov 2006 | A1 |
20060253168 | Wyler et al. | Nov 2006 | A1 |
20060253169 | Wyler et al. | Nov 2006 | A1 |
20060253170 | Wyler et al. | Nov 2006 | A1 |
20060253171 | Wyler et al. | Nov 2006 | A1 |
20060259095 | Wyler et al. | Nov 2006 | A1 |
20060264730 | Stivoric et al. | Nov 2006 | A1 |
20060265018 | Smith et al. | Nov 2006 | A1 |
20060271409 | Rosenfeld et al. | Nov 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20070027486 | Armstrong et al. | Feb 2007 | A1 |
20070032734 | Najafi et al. | Feb 2007 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070038262 | Kieval et al. | Feb 2007 | A1 |
20070043392 | Gliner et al. | Feb 2007 | A1 |
20070043400 | Donders et al. | Feb 2007 | A1 |
20070055320 | Weinand et al. | Mar 2007 | A1 |
20070073150 | Gopalsami et al. | Mar 2007 | A1 |
20070073346 | Corbucci et al. | Mar 2007 | A1 |
20070073355 | DiLorenzo | Mar 2007 | A1 |
20070078491 | Siejko et al. | Apr 2007 | A1 |
20070088403 | Wyler et al. | Apr 2007 | A1 |
20070088404 | Wyler et al. | Apr 2007 | A1 |
20070088405 | Jacobson et al. | Apr 2007 | A1 |
20070100278 | Frei et al. | May 2007 | A1 |
20070100397 | Seeberger et al. | May 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070112393 | Gliner et al. | May 2007 | A1 |
20070123946 | Masoud | May 2007 | A1 |
20070135855 | Foshee et al. | Jun 2007 | A1 |
20070142862 | DiLorenzo | Jun 2007 | A1 |
20070142873 | Esteller et al. | Jun 2007 | A1 |
20070149952 | Bland et al. | Jun 2007 | A1 |
20070150011 | Meyer et al. | Jun 2007 | A1 |
20070150014 | Kramer et al. | Jun 2007 | A1 |
20070150024 | Leyde et al. | Jun 2007 | A1 |
20070150025 | DiLorenzo et al. | Jun 2007 | A1 |
20070156179 | S.E. | Jul 2007 | A1 |
20070156450 | Roehm et al. | Jul 2007 | A1 |
20070156626 | Roehm et al. | Jul 2007 | A1 |
20070161919 | DiLorenzo | Jul 2007 | A1 |
20070162086 | DiLorenzo | Jul 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070173901 | Reeve | Jul 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070179584 | Gliner | Aug 2007 | A1 |
20070203548 | Pawelzik et al. | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070208390 | Von Arx et al. | Sep 2007 | A1 |
20070213785 | Osorio et al. | Sep 2007 | A1 |
20070233192 | Craig | Oct 2007 | A1 |
20070238939 | Giftakis et al. | Oct 2007 | A1 |
20070239210 | Libbus et al. | Oct 2007 | A1 |
20070239211 | Lorincz et al. | Oct 2007 | A1 |
20070239220 | Greenhut et al. | Oct 2007 | A1 |
20070244407 | Osorio | Oct 2007 | A1 |
20070249953 | Frei et al. | Oct 2007 | A1 |
20070249954 | Virag et al. | Oct 2007 | A1 |
20070250130 | Ball et al. | Oct 2007 | A1 |
20070250145 | Kraus et al. | Oct 2007 | A1 |
20070255147 | Drew et al. | Nov 2007 | A1 |
20070255155 | Drew et al. | Nov 2007 | A1 |
20070255330 | Lee et al. | Nov 2007 | A1 |
20070255337 | Lu | Nov 2007 | A1 |
20070260147 | Giftakis et al. | Nov 2007 | A1 |
20070260289 | Giftakis et al. | Nov 2007 | A1 |
20070265489 | Fowler et al. | Nov 2007 | A1 |
20070265508 | Sheikhzadeh-Nadjar et al. | Nov 2007 | A1 |
20070265536 | Giftakis et al. | Nov 2007 | A1 |
20070272260 | Nikitin et al. | Nov 2007 | A1 |
20070282177 | Pilz | Dec 2007 | A1 |
20070287931 | DiLorenzo | Dec 2007 | A1 |
20070288072 | Pascual-Leone et al. | Dec 2007 | A1 |
20070299349 | Alt et al. | Dec 2007 | A1 |
20070299473 | Matos | Dec 2007 | A1 |
20070299480 | Hill | Dec 2007 | A1 |
20080015651 | Ettori et al. | Jan 2008 | A1 |
20080015652 | Maile et al. | Jan 2008 | A1 |
20080021332 | Brainard, III | Jan 2008 | A1 |
20080021341 | Harris et al. | Jan 2008 | A1 |
20080021517 | Dietrich | Jan 2008 | A1 |
20080021520 | Dietrich | Jan 2008 | A1 |
20080027347 | Harris et al. | Jan 2008 | A1 |
20080027348 | Harris et al. | Jan 2008 | A1 |
20080027515 | Harris et al. | Jan 2008 | A1 |
20080033502 | Harris et al. | Feb 2008 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080033508 | Frei et al. | Feb 2008 | A1 |
20080039895 | Fowler et al. | Feb 2008 | A1 |
20080046035 | Fowler et al. | Feb 2008 | A1 |
20080046037 | Haubrich et al. | Feb 2008 | A1 |
20080046038 | Hill et al. | Feb 2008 | A1 |
20080051852 | Dietrich et al. | Feb 2008 | A1 |
20080058884 | Matos | Mar 2008 | A1 |
20080064934 | Frei et al. | Mar 2008 | A1 |
20080071323 | Lowry et al. | Mar 2008 | A1 |
20080077028 | Schaldach et al. | Mar 2008 | A1 |
20080081962 | Miller et al. | Apr 2008 | A1 |
20080082132 | Annest et al. | Apr 2008 | A1 |
20080103548 | Fowler et al. | May 2008 | A1 |
20080114417 | Leyde | May 2008 | A1 |
20080119900 | DiLorenzo | May 2008 | A1 |
20080125820 | Stahmann et al. | May 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
20080146890 | LeBoeuf et al. | Jun 2008 | A1 |
20080146959 | Sheffield et al. | Jun 2008 | A1 |
20080161712 | Leyde | Jul 2008 | A1 |
20080161713 | Leyde et al. | Jul 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161880 | Firlik et al. | Jul 2008 | A1 |
20080161881 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080183096 | Snyder et al. | Jul 2008 | A1 |
20080183097 | Leyde et al. | Jul 2008 | A1 |
20080183245 | Van Oort et al. | Jul 2008 | A1 |
20080195175 | Balzer et al. | Aug 2008 | A1 |
20080200925 | Johnson | Aug 2008 | A1 |
20080208013 | Zhang et al. | Aug 2008 | A1 |
20080208074 | Snyder et al. | Aug 2008 | A1 |
20080208285 | Fowler et al. | Aug 2008 | A1 |
20080208291 | Leyde et al. | Aug 2008 | A1 |
20080208781 | Snyder | Aug 2008 | A1 |
20080215112 | Firlik et al. | Sep 2008 | A1 |
20080215114 | Stuerzinger et al. | Sep 2008 | A1 |
20080221644 | Vallapureddy et al. | Sep 2008 | A1 |
20080234598 | Snyder et al. | Sep 2008 | A1 |
20080249591 | Gaw et al. | Oct 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20090018610 | Gharib et al. | Jan 2009 | A1 |
20090054795 | Misczynski et al. | Feb 2009 | A1 |
20090076567 | Fowler et al. | Mar 2009 | A1 |
Number | Date | Country |
---|---|---|
2339971 | Jun 2004 | CA |
0402683 | Dec 1990 | EP |
0713714 | May 1996 | EP |
1139861 | Dec 1999 | EP |
1070518 | Jan 2001 | EP |
0944411 | Apr 2001 | EP |
1145736 | Oct 2001 | EP |
1483020 | Dec 2004 | EP |
1486232 | Dec 2004 | EP |
1595497 | Nov 2005 | EP |
1120130 | Dec 2005 | EP |
1647300 | Apr 2006 | EP |
1202775 | Sep 2006 | EP |
2026870 | Feb 1980 | GB |
2079610 | Jan 1982 | GB |
9302744 | Feb 1993 | WO |
9417771 | Aug 1994 | WO |
0064336 | Nov 2000 | WO |
0108749 | Feb 2001 | WO |
0064336 | Jun 2002 | WO |
03085546 | Oct 2003 | WO |
2004036377 | Apr 2004 | WO |
2004064918 | Aug 2004 | WO |
2004069330 | Aug 2004 | WO |
2004071575 | Aug 2004 | WO |
2004075982 | Sep 2004 | WO |
2004112894 | Dec 2004 | WO |
2005007120 | Jan 2005 | WO |
2005007232 | Jan 2005 | WO |
2005028026 | Mar 2005 | WO |
2005053788 | Jun 2005 | WO |
2005067599 | Jul 2005 | WO |
2005101282 | Oct 2005 | WO |
2006014760 | Feb 2006 | WO |
2006019822 | Feb 2006 | WO |
2006050144 | May 2006 | WO |
2006122148 | Nov 2006 | WO |
2007066343 | Jun 2007 | WO |
2007072425 | Jun 2007 | WO |
2007124126 | Nov 2007 | WO |
2007124190 | Nov 2007 | WO |
2007124192 | Nov 2007 | WO |
2007142523 | Dec 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20070255351 A1 | Nov 2007 | US |